V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10420589 | 10057180 | 1.8 | 87 | Palliative (P) | 2019-09-28 | 2019-10-05 | Bendamustine +/- Prednisolone | 01 | N | IDELALISIB + RITUXIMAB | 100271492 |
| 10420691 | 10057183 | 1.78 | 89 | Palliative (P) | 2019-09-04 | 2019-09-04 | Doxorubicin + Olaratumab | 02 | N | STAMPEDE TRIAL | 101456989 |
| 10420727 | 10057184 | 1.7 | 82.05 | null | 2017-08-08 | 2017-08-10 | Pemetrexed | 02 | null | DOCETAXEL + FLUOROURACIL + OXALIPLATIN | 100157235 |
| 10420763 | 10057185 | 1.66 | 57.7 | null | 2018-09-27 | 2019-07-06 | ISATUXIMAB + POMALIDOMIDE | 01 | null | IXAZOMIB | 100620821 |
| 10420873 | 10057186 | 1.65 | 80.6 | Palliative (P) | 2017-01-13 | 2017-03-09 | CAV | 02 | N | IRINOTECAN + MDG | 100769892 |
| 10420884 | 10057187 | null | null | Adjuvant (A) | 2019-07-14 | 2019-08-04 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | N | AML18 TRIAL | 101818491 |
| 10420893 | 10057188 | 1.76 | 65.95 | null | 2019-01-26 | 2019-02-01 | AZACITIDINE + VENETOCLAX | 02 | null | CAPECITABINE + CARBOPLATIN | 101535454 |
| 10420990 | 10057190 | 1.81 | 78.5 | null | 2018-09-02 | 2018-09-02 | CYCLOPHOSPHAMIDE + ETOPOSIDE + LOMUSTINE | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100339899 |
| 10421080 | 10057193 | 0 | 0 | Palliative (P) | 2018-02-27 | 2018-03-15 | RIALTO TRIAL | 02 | N | DOCETAXEL + TRASTUZUMAB | 100973788 |
| 10421566 | 10057196 | 1.52 | 150 | null | 2019-06-09 | 2019-06-10 | Binimetinib + Encorafenib | 02 | null | CISPLATIN + GEMCITABINE + RITUXIMAB | 100888438 |
| 10421650 | 10057198 | 0 | 74.5 | null | 2018-11-27 | 2018-11-29 | LIPOSOMAL DAUNORUBICIN + CYTARABINE (Vyxeos) | 99 | null | SUNITINIB | 101465884 |
| 10421854 | 10057201 | 1.68 | 83 | Curative (C) | 2018-09-18 | 2018-10-03 | Binimetinib + Encorafenib | 02 | Y | BCG | 100849989 |
| 10421908 | 10057202 | 1.57 | 62.5 | null | 2020-01-06 | 2020-02-03 | PEMBROLIZUMAB + PEMETREXED | 02 | null | STAMPEDE TRIAL | 100609196 |
| 10421926 | 10057203 | 1.9 | 61 | null | 2018-08-25 | 2020-03-22 | Folfirinox/ Folfoxiri | 02 | null | FLUOROURACIL + MITOMYCIN | 101205507 |
| 10421958 | 10057204 | 1.86 | 77.8 | null | 2020-03-10 | 2020-03-10 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE | 02 | N | CISPLATIN + GEMCITABINE + RITUXIMAB | 100596182 |
| 10421984 | 10057205 | 1.58 | 121.5 | Neo-adjuvant (N) | null | 2020-06-02 | null | 02 | N | ANAGRELIDE | 100144954 |
| 10422194 | 10057206 | 1.8 | 71.8 | null | 2017-05-10 | 2017-05-12 | Cladribine + Rituximab | 02 | N | CHLORAMBUCIL + RITUXIMAB | 100340854 |
| 10422213 | 10057207 | 1.8 | 68.5 | null | null | 2021-05-18 | Rucaparib | 02 | N | ANAGRELIDE | 101302380 |
| 10422230 | 10057208 | 1.67 | 83 | null | 2019-01-25 | 2019-03-23 | Ribociclib | N | null | DOXORUBICIN + IFOSFAMIDE | 101658942 |
| 10422234 | 10057209 | 1.65 | 50.6 | null | 2017-06-14 | 2017-06-21 | Liposomal Doxorubicin 40mg/m2 | null | null | ISATUXIMAB + POMALIDOMIDE | 101395029 |
| 10422305 | 10057211 | 1.86 | 69.05 | Neo-adjuvant (N) | null | 2019-08-30 | Binimetinib + Encorafenib | 02 | N | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 100263951 |
| 10422447 | 10057213 | 1.6 | 59.1 | Palliative (P) | 2017-09-21 | 2017-09-26 | RCEOP | 02 | N | IDELALISIB + RITUXIMAB | 100159418 |
| 10422449 | 10057214 | 1.73 | 75 | null | 2019-05-13 | 2019-05-23 | Etoposide oral | 02 | null | CISPLATIN + GEMCITABINE + RITUXIMAB | 100484608 |
| 10422545 | 10057215 | 0 | 0 | null | 2017-11-14 | 2017-11-14 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | null | DOXORUBICIN + OLARATUMAB | 101696199 |
| 10422815 | 10057218 | 1.77 | 0 | Palliative (P) | 2019-11-06 | 2019-11-06 | null | 02 | N | PAZOPANIB | 100798178 |
| 10423089 | 10057220 | 1.72 | 90.7 | null | 2019-07-27 | 2019-08-04 | Carboplatin + Pembrolizumab + Pemetrexed | 02 | null | BRENTUXIMAB | 101646647 |
| 10423155 | 10057222 | null | null | null | 2017-03-05 | 2018-02-28 | BLEOMYCIN + CYCLOPHOSPHAMIDE + ETOPOSIDE + MITOXANTRONE + VINCRISTINE | 02 | null | ZANUBRUTINIB | 101394410 |
| 10423209 | 10057223 | 1.66 | 59.7 | null | 2020-11-24 | 2020-12-05 | Gemcitabine + Capecitabine | 02 | null | ERIBULIN | 100991386 |
| 10423284 | 10057224 | 1.57 | 89.8 | null | 2022-05-29 | 2022-05-29 | Doxorubicin chemoembolisation | 02 | null | CYTARABINE + DAUNORUBICIN | 100534484 |
| 10423408 | 10057227 | 1.65 | 83 | null | 2019-05-10 | 2019-05-10 | Paclitaxel albumin (Abraxane) 21day | 02 | null | LORLATINIB | 101443785 |
| 10423496 | 10057229 | 1.73 | 73.9 | null | 2019-02-04 | 2019-02-04 | Doxorubicin + Olaratumab | 02 | null | CISPLATIN + CYTARABINE + ETOPOSIDE + RITUXIMAB | 100207489 |
| 10423503 | 10057230 | 1.61 | 96.2 | null | 2020-04-14 | 2020-04-17 | null | 02 | null | OBINUTUZUMAB | 101596273 |
| 10423604 | 10057234 | 1.69 | 67.5 | null | 2020-03-16 | 2020-05-19 | Binimetinib + Encorafenib | null | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100206028 |
| 10423791 | 10057236 | 1.53 | 96.75 | null | 2015-04-21 | 2017-12-01 | Docetaxel + nintedanib | 02 | null | LANREOTIDE | 100892916 |
| 10423965 | 10057237 | 1.71 | 68 | Palliative (P) | 2019-10-01 | 2019-10-05 | Irinotecan | 02 | N | CLADRIBINE | 100092178 |
| 10424062 | 10057238 | 0 | 55.5 | Palliative (P) | 2021-07-06 | 2021-09-25 | AXITINIB | 02 | null | CARFILZOMIB | 100890552 |
| 10424086 | 10057239 | null | null | Palliative (P) | 2017-03-09 | 2017-03-09 | AML 18 TRIAL | N | N | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | 100084528 |
| 10424156 | 10057241 | null | null | Curative (C) | 2015-10-26 | 2015-10-26 | CHLVPP | Y | N | IPILIMUMAB | 100838723 |
| 10424217 | 10057242 | 1.6 | 83 | Curative (C) | 2021-11-25 | 2021-12-03 | BEAM | 02 | N | VEDEX | 100797611 |
| 10424249 | 10057243 | 1.75 | 87.6 | null | 2018-02-21 | 2018-02-21 | null | 02 | null | BENDAMUSTINE + OBINUTUZUMAB | 101457484 |
| 10424518 | 10057246 | 1.7 | 97.8 | null | 2019-12-29 | 2020-01-19 | PONATINIB | 02 | null | IRINOTECAN | 100596855 |
| 10424593 | 10057247 | 0 | 63 | null | 2015-04-12 | 2016-10-24 | EC | N | null | CHLORAMBUCIL + RITUXIMAB | 101145112 |
| 10424962 | 10057249 | 1.54 | 79.6 | Palliative (P) | 2017-09-06 | 2017-09-06 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 01 | N | FLUOROURACIL + MITOMYCIN | 100264363 |
| 10425011 | 10057251 | 1.73 | 72 | null | 2019-04-04 | 2019-04-22 | Bevacizumab | 02 | null | STAMPEDE TRIAL | 100617632 |
| 10425270 | 10057253 | 1.51 | 71.2 | null | 2018-04-06 | 2018-04-20 | ICON8B TRIAL | 02 | null | VINCRISTINE | 100924995 |
| 10425354 | 10057256 | 0 | 83 | Palliative (P) | 2019-09-22 | 2019-10-03 | NEPTUNE TRIAL | 02 | N | BORTEZOMIB + MELPHALAN | 100309174 |
| 10425497 | 10057257 | 1.59 | 0 | null | 2016-11-02 | 2019-08-16 | LENALIDOMIDE + RITUXIMAB | 02 | null | PEG INTERFERON | 100315768 |
| 10425550 | 10057258 | 1.83 | 79.6 | Palliative (P) | 2019-08-24 | 2019-08-31 | Bevacizumab | 01 | N | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101617849 |
| 10425714 | 10057259 | 1.59 | 76.6 | Palliative (P) | 2021-10-16 | 2021-10-16 | CARFILZOMIB | 1 | N | FLAIR TRIAL | 100612156 |
| 10425811 | 10057262 | 1.69 | 62 | null | 2021-11-08 | 2021-11-08 | Irinotecan + Modified De Gramont | 02 | null | TOPOTECAN | 100147381 |